gIcare pharma is a clinical-stage, GI specialty company specialized in the development of novel colonic analgesic drugs for the visceral pain management of patients undergoing sedation-free, full colonoscopy. Such colonic analgesic drugs are non-centrally-acting opioid agonist with affinity to kappa and mu opioid receptor, capable of releasing a gaseous mediator, hydrogen sulfide. Colonoscopy is a major burden for governments and third-party payers, especially in the US. Sedation-related costs exceed 25% of the overall colonoscopy cost, due to special assistance (anesthesiologist, nurse anesthetist) and the recovery room, in addition to drug administration system and the drugs themselves.
| Website | http://www.gicarepharma.com |
| Revenue | $8 million |
| Employees | 3 (0 on RocketReach) |
| Founded | 2011 |
| Address | 2202 Oxford, Montreal, Quebec H4A 2X8, CA |
| Industry | Pharmaceutical Manufacturing, Pharmaceuticals, Healthcare, Drug Manufacturing & Research, Biotechnology |
| Keywords | Colonoscopy Preparation, Innovative Pain Relief, Pharmaceutical Research, Digestive Health Solutions, Drug Discovery And Development |
| Competitors | AstraZeneca, Bristol Myers Squibb, Teva Pharmaceuticals, AbbVie, Pfizer, Sanofi, GSK, Merck & Co., Inc., Roche, Novartis +42 more (view full list) |
| SIC | SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular gIcare pharma inc employee's phone or email?
gIcare pharma inc Questions
The gIcare pharma inc annual revenue was $8 million in 2026.
gIcare pharma inc is based in Montreal, Quebec.
The NAICS codes for gIcare pharma inc are [32541, 3254, 325, 32].
The SIC codes for gIcare pharma inc are [2834, 28, 283].
Related Companies
